Activity-Dependent Neuroprotective Protein (ADNP) Expression in the Amyloid Precursor Protein/Presenilin 1 Mouse Model of Alzheimer’s Disease

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Molecular Neuroscience

• Publication date

  2010-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12031-009-9300-xPMID 19844808
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Survival in Alzheimer disease: A multiethnic, population-based study of incident cases

  2009cited by this paper
• Addressing Alzheimer's disease tangles: from NAP to AL-108.

  2009cited by this paper
• The health-care in the extreme longevity.

  2009cited by this paper
• Recruitment of adult-generated neurons into functional hippocampal networks contributes to updating and strengthening of spatial memory

  2009cited by this paper
• A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

  2008cited by this paper
• Alzheimer researchers focus efforts on early development and earlier detection.

  2008cited by this paper
• Neuroscience: The plaque plan

  2008cited by this paper
• Alzheimer Disease Pathology As a Host Response

  2008cited by this paper
• Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics

  2008cited by this paper
• Survival in Alzheimer disease

  2008cited by this paper
• Animal models of Alzheimer's disease and frontotemporal dementia

  2008cited by this paper
• Inflammatory Response in the Hippocampus of PS1M146L/APP751SL Mouse Model of Alzheimer's Disease: Age-Dependent Switch in the Microglial Phenotype from Alternative to Classic

  2008influential reference
• Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease

  2008cited by this paper
• Therapeutic Strategies for Alzheimer’s Disease

  2008cited by this paper
• VIP, From Gene to Behavior and Back: Summarizing my 25 Years of Research

  2008cited by this paper
• Still debating a cause and diagnostic criteria for Alzheimer's disease

  2007influential reference
• Abeta, tau and ApoE4 in Alzheimer's disease: the axonal connection.

  2007cited by this paper
• Brain injury-dependent expression of activity-dependent neuroprotective protein

  2007cited by this paper
• Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention

  2007cited by this paper
• Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis.

  2007influential reference
• Activity-dependent neuroprotective protein: from gene to drug candidate.

  2007cited by this paper
• Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease.

  2007cited by this paper
• Looking for novel ways to treat the hallmarks of Alzheimer's disease

  2007cited by this paper
• Alzheimer's-Type Amyloidosis in Transgenic Mice Impairs Survival of Newborn Neurons Derived from Adult Hippocampal Neurogenesis

  2007cited by this paper
• Systemic infections and inflammation affect chronic neurodegeneration

  2007cited by this paper
• Tubulin is the target binding site for NAP-related peptides

  2007cited by this paper
• NAP, a Peptide Derived from the Activity‐Dependent Neuroprotective Protein, Modulates Macrophage Function

  2006influential reference
• The influence of the peptide NAP on Mac-1-deficient mice following closed head injury.

  2005cited by this paper
• A Femtomolar Acting Octapeptide Interacts with Tubulin and Protects Astrocytes against Zinc Intoxication*

  2004cited by this paper
• Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze.

  2004cited by this paper
• Activity-dependent neuroprotective protein: a novel gene essential for brain formation.

  2003cited by this paper
• Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice.

  2003influential reference
• Progressive age-related impairment of cognitive behavior in APP23 transgenic mice.

  2003cited by this paper
• Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development.

  2002cited by this paper
• Therapeutic strategies for Alzheimer's disease

  2002cited by this paper
• 48 Differential expression of embryonic and maternal activity dependent neuroprotective protein (ADNP) during development

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Cloning and Characterization of the Human Activity-dependent Neuroprotective Protein*

  2001cited by this paper
• Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze.

  2000cited by this paper
• Complete Sequence of a Novel Protein Containing a Femtomolar‐Activity‐Dependent Neuroprotective Peptide

  1999influential reference
• A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage.

  1996cited by this paper
• Vasoactive intestinal peptide gene expression from embryos to aging rats.

  1988cited by this paper
• Somatostatin and vasoactive intestinal polypeptide in postmortem brains from patients with Alzheimer-type dementia.

  1984cited by this paper

• Integrated ribosome and proteome analyses reveal insights into sevoflurane-induced long-term social behavior and cognitive dysfunctions through ADNP inhibition in neonatal mice

  2024cites this paper
• Chromatin remodeler Activity-Dependent Neuroprotective Protein (ADNP) contributes to syndromic autism

  2023cites this paper
• Capillary electrophoresis in the analysis of therapeutic peptides—A review

  2023cites this paper
• Peptide LIQ promotes cell protection against zinc-induced cytotoxicity through microtubule stabilization.

  2020cites this paper
• Reduction of aluminum ion neurotoxicity through a small peptide application – NAP treatment of Alzheimer’s disease

  2019cites this paper
• Peptide based therapeutics and their use for the treatment of neurodegenerative and other diseases.

  2018cites this paper
• The effects of vasoactive intestinal peptide in neurodegenerative disorders

  2017cites this paper
• Davunetide improves spatial learning and memory in Alzheimer's disease-associated rats.

  2017cites this paper
• Transcriptional Effects of ApoE4: Relevance to Alzheimer’s Disease

  2017cites this paper
• The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP

  2016cites this paper
• A Subset of Autism-Associated Genes Regulate the Structural Stability of Neurons

  2016cites this paper
• Direct Transcriptional Effects of Apolipoprotein E

  2016cites this paper
• Microtubule stabilising peptides rescue tau phenotypes in-vivo

  2016cites this paper
• Neurobiology of Disease Direct Transcriptional Effects of Apolipoprotein E

  2016cites this paper
• Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease

  2016cites this paper
• Pharmacological approaches for Alzheimer’s disease: neurotransmitter as drug targets

  2015influential citation
• Investigation of neurodegenerative diseases from body fluid samples using Fourier transform infrared spectroscopy

  2015cites this paper
• Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer’s Disease Biomarkers

  2015cites this paper
• Novel Marker for the Onset of Frontotemporal Dementia: Early Increase in Activity-Dependent Neuroprotective Protein (ADNP) in the Face of Tau Mutation

  2014cites this paper
• Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.

  2014cites this paper
• Davunetide: Peptide therapeutic in neurological disorders.

  2014cites this paper
• Peptide therapeutics in neurodegenerative disorders.

  2014cites this paper
• Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics

  2014cites this paper
• Is NAP an additional neuroprotector in Alzheimer's disease?

  2013cites this paper
• Neurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic Lateral Sclerosis and Alzheimer's disease.

  2013cites this paper
• Tau and Caspase 3 as Targets for Neuroprotection

  2012cites this paper
• Vitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology

  2012cites this paper
• Activity-dependent neuroprotector homeobox protein: A candidate protein identified in serum as diagnostic biomarker for Alzheimer's disease.

  2012cites this paper
• Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy.

  2011cites this paper
• Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo.

  2011cites this paper
• Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).

  2011cites this paper
• NAP (davunetide) provides functional and structural neuroprotection.

  2011cites this paper
• Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.

  2011cites this paper